Tested Applications
| Positive WB detected in | MCF-7 cells, A431 cells, U-251 cesll, U-87 MG cells, T-47D cells, MDA-MB-231 cells, HUVEC cells, RAW 264.7 cells |
| Positive IF/ICC detected in | HeLa cells, MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
81323-2-RR targets VEGFA in WB, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
CatNo: Ag13500 Product name: Recombinant human VEGFA protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-302 aa of BC065522 Sequence: AAASRGQGPEPAPGGGVEGVGARGVALKLFVQLLGCSRFGGAVVRAGEAEPSGAARSASSGREEPQPEEGEEEEEKEEERGPQWRLGARKPGSWTGEAAVCADSAPAARAPQALARASGRGGRVARRGAEESGPPHSPSRRGSASRAGPGRASETMNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKCDKPRR Predict reactive species |
| Full Name | vascular endothelial growth factor A |
| Calculated Molecular Weight | 412 aa, 46 kDa |
| Observed Molecular Weight | 40 kDa |
| GenBank Accession Number | BC065522 |
| Gene Symbol | VEGFA |
| Gene ID (NCBI) | 7422 |
| RRID | AB_3086457 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P15692 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are associated with microvascular complications of diabetes type 1 (MVCD1). VEGFA has 17 isoforms with MW from 16 to 45 kDa. Some isoforms have homodimer forms (e.g.; VEGFA189 38 kDa or VEFGA110 34 kDa). VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids (PMID:15602010 ).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for VEGFA antibody 81323-2-RR | Download protocol |
| WB protocol for VEGFA antibody 81323-2-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The VEGFA Recombinant monoclonal antibody (7H10), catalog number 81323-2-RR, has accumulated 39 citations across journals including Biomaterials, Mater Today Bio, J Transl Med, Apoptosis, iScience, J Biol Chem, Diabetes, Life Sci, and Theranostics. Research fields span angiogenesis, diabetic wound healing, tumor microenvironment (HCC, glioblastoma, colorectal cancer), diabetic retinopathy, ferroptosis, nanomedicine, and vascular inflammation.
| Species | Application | Title |
|---|---|---|
Redox Biol Phytochemical nanozymes reprogram redox for balanced antimicrobial and regenerative therapy in acute and chronic diabetic wounds | ||
J Nanobiotechnology High glucose-primed HUVEC-derived extracellular vesicles encapsulated in microgels boost diabetic ischaemic flap regeneration via HIF-1α/VEGF pathway. | ||
Biomaterials Chiral nanoassembly remodels tumor microenvironment through non-oxygen-dependent depletion lactate for effective photodynamic immunotherapy | ||
Biomaterials Tannic acid-reinforced anisotropic polyvinyl alcohol hydrogel for urethral stricture reconstruction. | ||
J Control Release Hyaluronic acid methacryloyl-based co-delivery system for aflibercept and miR-21-3p antagomir: a dual-therapeutic approach for diabetic retinopathy | ||
Mater Today Bio Bionic intelligent responsive barbed microneedles synergistically remodel the microenvironment for the treatment of refractory pigmentation disorders (melasma). |









